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There are an estimated five women per million in the United States who suffer from lymphangio leiomyomatosis (LAM), a rare and devastating disease that almost exclusively strikes young women. 1-3 These patients have progressive loss of lung function, and many die from respiratory failure. Until recently, a diagnosis of LAM was a medical anomaly, and a woman who received this diagnosis had little cause for hope. The dis ease was likely to be managed symptomatically by physicians unfamiliar with the disease.
That all changed about 15 years ago, when LAM was diagnosed in a 22yearold woman who had a bleak picture painted of her future. Her mother, who was not a medical professional, re alized that very little was known about LAM, and that without an understanding of the patho biology of the disease, effective treatments, or even cures, would never be forthcoming. With her tremendous drive and the networking power of the fledgling Internet, the LAM Foundation was born. The LAM Foundation succeeded in raising money and obtaining thirdparty fund ing for research into the biology of LAM. 4,5 As a result of the work funded by the foundation, we now know that LAM is characterized by the pres ence in the circulation of socalled LAM cells. These are specialized cells, with certain charac teristics of smoothmuscle cells, that infiltrate organs, especially the lungs and to some extent the kidneys and other organs, via the lymphatics. The spread of these unusual cells leads some to categorize LAM as a lowgrade neoplasm.
The increased understanding of the biology of LAM led next to treatment trials. These trials were feasible because patients with LAM were no longer impossibly hard to find. Rather, they had banded together not only to raise and secure research funding, but to place themselves at risk in clinical trials that were designed to study po tential treatments for this rare condition. In this issue of the Journal, McCormack et al. 6 report the results of the Multicenter International Lymph angioleiomyomatosis Efficacy and Safety of Si rolimus trial (MILES; ClinicalTrials.gov number, NCT00414648), which confirm observations from uncontrolled pilot studies 7,8 that had indicated that sirolimus, an inhibitor of mammalian tar get of rapamycin (mTOR), may ameliorate the course of this disease.
Sirolimus (also called rapamycin), which is used widely in the treatment of a variety of cancers and as an immunosuppressive agent in patients undergoing solidorgan transplantation, inhibits mTOR. Since research had shown that mTOR signaling is inappropriately activated in LAM, and mTOR regulates lymphangiogenesis and cell growth, it made sense to try sirolimus as a treatment for LAM. [9] [10] [11] [12] The MILES trial had two stages -a 12month, randomized, doubleblind trial that compared sirolimus with placebo, followed by a year of ob servation in which none of the patients were re ceiving the study treatment. The primary outcome, the difference between the treatment groups in the rate of change in the forced expiratory volume in 1 second (FEV 1 ), was positive, though not in every patient; in the group that received the ac tive drug, pulmonary function was stabilized, whereas in the group that received the placebo, pulmonary function deteriorated. There were some reductions in symptoms and improve ments in quality of life among patients in the sirolimus group, as compared with those in the placebo group. However, the differences between the groups reverted once the drug was stopped.
These data suggest that there is a need for con tinued sirolimus therapy, which requires consid eration of its longterm toxic effects.
Even though these data offer women with LAM the prospect of only a longterm treatment rather than a cure, this is a big step forward. Twenty years ago, it would have been impossible to make this much progress in such a rare dis ease. This research study shows that when pa tients and researchers work together toward a common goal, advances can be made. The re search community contributes ideas and investi gative knowhow, and patients who have the ill ness contribute their personal insights, biologic samples, and their time to prove principles. Most important, patients with such a rare disease are willing to put themselves at risk in order to find a treatment or a cure. This takes dedication and courage, and the women with LAM who partici pated in this work had both.
LAM is not the only medical condition in which patient groups have sponsored both clini cal and basic research, have located patients to participate in trials, and have enlisted the help of expert clinicians and investigators. Other ex amples are cystic fibrosis, Huntington's disease, Waldenström's macroglobulinemia, oxalosis and primary hyperoxaluria, cystinosis, autosomal re cessive polycystic kidney disease, and Duchenne's muscular dystrophy, to name just a few. In each case, patients have formed groups to drive re search aimed at understanding and treating their particular illness. The key to success for such groups has been to support basic research that is held to the highest scientific standards. When appropriate, they can take the results of the basic work forward to test hypotheses in pa tients. Trials involving patients with the disease will help illuminate whether the investigators are headed in the right direction and will lead to more focused basic research and better ideas to test in patients. This is true "bench to bedside and back" research that fits the Pareto principle 13 of factor sparsity -in which the affected pa tients are the vital few and those caring for them work together with professional researchers to advance the field. It is a good model to emulate.
